St. Jude Care & Treatment

Menu

Close

Recruiting

4WARD: Mavorixafor for Chronic Neutropenia

About this study

Neutrophils are a type of white blood cell that helps fight germs. People who have low numbers of neutrophils in their blood have neutropenia. People with neutropenia may have a higher risk for infections that can be serious or even life threatening. Current treatments may not always prevent these infections or work well for everyone. We want to find better ways to help the neutrophil numbers go up to avoid these infections.

A new medicine called mavorixafor may help people with chronic neutropenia. It is taken by mouth once every day. Some people in the 4WARD study will get mavorixafor and others will get a placebo, which looks like the medicine but has no active drug. Neither the patients nor the doctors will know who is getting the real medicine or the placebo. This helps make the results fair and reliable. Participants will continue any current treatments they are already taking. 

The study will look at how well mavorixafor works to help the body make more neutrophils and lower the number and severity of infections. Researchers will watch for any side effects that might happen while taking the medicine. Everyone will be followed for about 52 weeks to see how they do over time. 

At the end of the study, researchers want to learn if mavorixafor can help people with chronic neutropenia stay healthier and avoid serious infections. Results of this trial could help guide future treatments.

Eligibility overview

  • 12 years old or older
  • Chronic neutropenia that has lasted at least 6 months
  • Has had 2 or more serious or repeated infections in the past year
  • Neutropenia is not caused by cancer, infections, or certain medicines.

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

4WARD: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Participants with Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Study goal:

To study mavorixafor as an oral treatment to raise neutrophil counts and reduce infections in chronic neutropenia.

Diagnosis:

Chronic Neutropenia 

Age:

12 years and older

Clinical trial categories:

Blood Disorders Immune Disorders

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more